undamentalytics Newsletter
Sign in

Avalo Therapeutics, Inc. revenue

Avalo Therapeutics, Inc.'s revenue was $59,000 in fiscal 2025, down 86.6% on the year before. Since fiscal 2016 ($1.2m) it has grown at a compound -28.1% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue0128777518200
Growth on the year before——+>999%−74.7%−4.0%−0.8%−19.4%+234.4%−89.3%−77.1%−86.6%
Gross profit——274764151——
Gross margin——97.7%53.6%—95.5%72.4%81.0%33.3%——

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Avalo Therapeutics, Inc. $441,000 -77.1% -56.6%
Cardiff Oncology, Inc. $508,000 -7.0% 7.2%
Cervomed Inc. $331,295 -95.7% -52.7%
Medicinova Inc $920,481 875.7% —
Clene Inc. $197,000 -31.1% -36.9%
Shattuck Labs, Inc. $1.0m -66.6% 5.2%

Compare with peers

Head to head: AVTX vs CRDFAVTX vs CRVOAVTX vs MNOV

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Avalo Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Avalo Therapeutics, Inc.